U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874725) titled 'Latent Tuberculosis in Type 2 Diabetes' on March 08.
Brief Summary: The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.
Study Start Date: April 18, 2018
Study Type: INTERVENTIONAL
Condition:
Latent Tuberculosis Infection
Intervention:
DRUG: Rifapentine and Isoniazid for 3 months
tuberculosis p...